Imidazo[1,2-a]pyridines. Part 2: SAR and optimisation of a potent and selective class of cyclin-dependent kinase inhibitors
- 3 May 2004
- journal article
- research article
- Published by Elsevier BV in Bioorganic & Medicinal Chemistry Letters
- Vol. 14 (9), 2245-2248
- https://doi.org/10.1016/j.bmcl.2004.02.015
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Synthesis and Evaluation of Indenopyrazoles as Cyclin-Dependent Kinase Inhibitors. 3. Structure Activity Relationships at C3Journal of Medicinal Chemistry, 2002
- Structure-Based Generation of a New Class of Potent Cdk4 Inhibitors: Newde NovoDesign Strategy and Library DesignJournal of Medicinal Chemistry, 2001
- S and G2 Phase Roles for Cdk2 Revealed by Inducible Expression of a Dominant-Negative Mutant in Human CellsMolecular and Cellular Biology, 2001
- Pyrido[2,3-d]pyrimidin-7-one Inhibitors of Cyclin-Dependent KinasesJournal of Medicinal Chemistry, 2000
- Preclinical and Clinical Development of Cyclin-Dependent Kinase ModulatorsJNCI Journal of the National Cancer Institute, 2000
- Cyclin-Dependent Kinase Inhibitors: Useful Targets in Cell Cycle RegulationJournal of Medicinal Chemistry, 2000
- Anticancer drug targets: cell cycle and checkpoint controlJCI Insight, 1999
- Cdk Phosphorylation Triggers Sequential Intramolecular Interactions that Progressively Block Rb Functions as Cells Move through G1Cell, 1999
- Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonistsProceedings of the National Academy of Sciences of the United States of America, 1999
- Cancer Cell CyclesScience, 1996